Evotec stock edges lower ahead of the open after a 1.6 percent Xetra drop
Published on 09/10/2026 at 07:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock closed at EUR 3.16 on Xetra on September 8, 2026, marking a 1.62% decline from the previous EUR 3.21 close according to Xetra data summarized by Ad-hoc-news. The shares traded between an intraday low near EUR 3.14 and a high around EUR 3.21 during the session, leaving the close in the middle of that range.
September 8, 2026 in numbers
Evotec SE (ISIN DE0005664809) ended Xetra trading on September 8, 2026 at EUR 3.16, down 1.62% from the prior EUR 3.21 finish per Xetra figures reported by Ad-hoc-news. The move came against a broadly mixed backdrop for German equities, with the DAX showing only modest day-to-day fluctuations in early September, highlighting that Evotec underperformed the large-cap benchmark on that date. The intraday range between roughly EUR 3.14 and EUR 3.21 indicates limited volatility in absolute terms, even as the percentage move was notable relative to the low price level. The resulting EUR 0.05 drop versus the prior close reflects continued pressure on the stock in recent sessions.
Pipeline news today
Today, attention turns to fresh pipeline news from Evotec. As TipRanks reported on September 9, 2026, Evotecs CDMO subsidiary Just Evotec Biologics has initiated a first-in-human Phase 1 clinical trial of JST-018, a monoclonal antibody cocktail targeting orthopoxviruses under a U.S. biodefense program. This kind of development-stage milestone can influence sentiment around Evotecs broader therapeutics pipeline and contract development activities today. In addition, investors may track global economic data releases scheduled for September 10, 2026, including U.S. inflation indicators highlighted in economic calendars such as the one maintained by TradingCharts, given the sensitivity of growth-oriented and biotechnology shares to changes in interest rate expectations.
